Choroidal Neovascularization Industry

Summary:

• The global choroidal neovascularization market size reached USD 6.5 Billion in 2023.
• The market is expected to reach USD 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.
• Region-wise, the market has been divided into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
• Based on the product type, the market has been bifurcated into intravenous and intravitreal.
• On the basis of the type of diagnosis, the market has been classified into fluorescein angiography (FA), indocyanine green (ICG) angiography, spectral domain optical coherence tomography (OCT), and others.
• Based on the treatment type, the market has been categorized into angiogenesis inhibitors injection, photodynamic therapy, laser photocoagulation, low-dose radiation therapy, and surgery.
• On the basis of the application, the market has been classified into extreme myopia, malignant myopic degeneration, and age-related developments.
• The increasing incidences of eye disorders are a primary driver of the choroidal neovascularization market.
• The choroidal neovascularization market growth and forecast highlight a significant rise due to advancements in treatment options and the growing personalized medicine industry.

Industry Trends and Drivers:

• Rising Incidence of Eye Diseases:

The growing prevalence of age-related macular degeneration (AMD) and other ocular diseases is a key factor driving choroidal neovascularization demand for treatments. As populations age worldwide, the incidence of eye conditions linked to aging, such as AMD, is steadily increasing. Additionally, AMD and similar disorders can lead to CNV, where abnormal blood vessel growth beneath the retina threatens vision. This rise in cases has created an urgent need for effective therapies to preserve vision and manage symptoms, spurring patients and healthcare providers to seek advanced treatment options. Furthermore, lifestyle factors such as increased screen time, environmental pollution, and poor diet are contributing to ocular health challenges even in younger demographics, broadening the demand for CNV-related therapies. As public health systems and healthcare providers brace for an increase in vision-related ailments, the CNV treatment market is expected to see sustained growth due to the increasing need to cater to a diverse patient base with varying levels of risk.

• Advancements in Treatment Options:

The choroidal neovascularization market trends indicate that recent innovations in therapeutic options for CNV have transformed the landscape of treatment, with anti-vascular endothelial growth factor (VEGF) therapies at the forefront. Additionally, anti-VEGF treatments, which inhibit abnormal blood vessel growth, have shown substantial success in managing CNV, reducing vision loss, and, in some cases, restoring sight. These advancements represent a shift toward more precise and effective care, which greatly enhances patient outcomes and satisfaction. Moreover, the success of these therapies has attracted significant investment, prompting research organizations and pharmaceutical companies to develop even more targeted options, thus driving the choroidal neovascularization market share. Besides, newer delivery methods, such as longer-acting injections and potential oral formulations, are being explored to reduce the burden of frequent treatments, a major consideration for patients. As new therapies become available, CNV treatment is evolving toward increasingly patient-friendly approaches that align with the broader goal of improving the quality of life for individuals affected by ocular diseases.

• Growing Personalized Medicine Industry:

The personalized medicine trend is making a profound impact in ophthalmology, particularly in the treatment of CNV, by allowing therapies to be customized to a patient's unique genetic profile, disease progression, and lifestyle. Additionally, personalized treatments can increase efficacy and reduce the likelihood of adverse effects, addressing the specific needs of each patient. This approach is especially appealing in the field of CNV, where patients may respond differently to conventional therapies. Moreover, innovations in genetic testing and biomarker identification allow clinicians to predict a patient’s response to treatment better, guiding the selection of optimal therapies, which is driving the choroidal neovascularization market size. Besides, healthcare providers and patients are widely favoring this tailored approach, as it aligns to achieve better outcomes and minimize side effects. This growing preference for individualized care encourages ongoing research into CNV-specific therapies, ensuring the market remains dynamic and focused on developing advanced, targeted solutions that meet the evolving needs of patients and healthcare providers.

Request Sample For PDF Report: https://www.imarcgroup.com/choroidal-neovascularization-market/requestsample

Choroidal Neovascularization Market Report Segmentation:

Breakup By Product Type:

• Intravenous
• Intravitreal

Based on the product type, the market has been bifurcated into intravenous and intravitreal.

Breakup By Type of Diagnosis:

• Fluorescein Angiography (FA)
• Indocyanine Green (ICG) Angiography
• Spectral Domain Optical Coherence Tomography (OCT)
• Others

On the basis of the type of diagnosis, the market has been classified into fluorescein angiography (FA), indocyanine green (ICG) angiography, spectral domain optical coherence tomography (OCT), and others.

Breakup By Treatment Type:

• Angiogenesis Inhibitors Injection
• Photodynamic Therapy
• Laser photocoagulation
• Low-dose Radiation Therapy
• Surgery

Based on the treatment type, the market has been categorized into angiogenesis inhibitors injection, photodynamic therapy, laser photocoagulation, low-dose radiation therapy, and surgery.

Breakup By Application:

• Extreme Myopia
• Malignant Myopic Degeneration
• Age-Related Developments

On the basis of the application, the market has been classified into extreme myopia, malignant myopic degeneration, and age-related developments.

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Top Choroidal Neovascularization Market Leaders: 

• Bausch Health Companies Inc.
• Bayer AG
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche AG
• MaaT Pharma
• Novartis AG
• Pfizer Inc.
• Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
• Regeneron Pharmaceuticals Inc.
• Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.